Phase 1 study of the E-selectin inhibitor GMI 1070 in patients with sickle cell anemia
about
Biomarkers and recent advances in the management and therapy of sickle cell disease2015 Clinical trials update in sickle cell anemiaAn Analysis of Trafficking Receptors Shows that CD44 and P-Selectin Glycoprotein Ligand-1 Collectively Control the Migration of Activated Human T-Cells.Glycans and glycan-binding proteins in immune regulation: A concise introduction to glycobiology for the allergistRole of siglecs and related glycan-binding proteins in immune responses and immunoregulationRandomized phase 2 study of GMI-1070 in SCD: reduction in time to resolution of vaso-occlusive events and decreased opioid use.Single-dose intravenous gammaglobulin can stabilize neutrophil Mac-1 activation in sickle cell pain crisis.Platelet-neutrophil interactions under thromboinflammatory conditionsNeutrophils, platelets, and inflammatory pathways at the nexus of sickle cell disease pathophysiology.Beyond hydroxyurea: new and old drugs in the pipeline for sickle cell disease."Siglec"ting the allergic response for therapeutic targeting.Base-modified UDP-sugars reduce cell surface levels of P-selectin glycoprotein 1 (PSGL-1) on IL-1β-stimulated human monocytes.Recent Developments in Synthetic Carbohydrate-Based Diagnostics, Vaccines, and Therapeutics.Biological roles of glycans.Markers of endothelial dysfunction and leucocyte activation in Saudi and non-Saudi haplotypes of sickle cell disease.Glycobiology of Eosinophilic Inflammation: Contributions of Siglecs, Glycans, and Other Glycan-Binding Proteins.The Use of Cannabis by Patients with Sickle Cell Disease Increased the Frequency of Hospitalization due to Vaso-Occlusive CrisesSelectin catch-bonds mechanotransduce integrin activation and neutrophil arrest on inflamed endothelium under shear flow.The Bruton's tyrosine kinase inhibitor PRN473 inhibits neutrophil recruitment via inhibition of Mac-1 signaling.Dose Selection Based on Modeling and Simulation for Rivipansel in Pediatric Patients Aged 6 to 11 Years With Sickle Cell Disease.Heparin Mimetics: Their Therapeutic Potential.Safety and efficacy of plerixafor dose escalation for the mobilization of CD34+ hematopoietic progenitor cells in patients with sickle cell disease: interim results.Developing new pharmacotherapeutic approaches to treating sickle-cell disease.Dormant breast cancer micrometastases reside in specific bone marrow niches that regulate their transit to and from bone.Prospects for early investigational therapies for sickle cell disease.
P2860
Q28082462-AA8F4527-6012-445B-BE9B-32F43CC7EC4EQ28086979-ABF18C24-99DB-4299-AFBF-55509CD83526Q29994863-B253EF4E-EEE4-4324-BC49-762D1358F6E7Q35163983-FA675F90-0541-4452-A537-D52EA5A27AF6Q35164415-730E23D8-2063-43AA-9353-1B9619D6C13BQ35533604-A1416C34-FD07-4D6C-9CB5-F6A585B7ADD2Q35537053-05E8C352-4374-4BE3-A682-A96973C5ADEFQ35779411-E912EC4B-05E6-4073-B5FF-E34275AD258CQ36596850-8B03A71E-777A-466C-9073-2A9897897485Q36596855-325162B4-D634-4998-AB30-20E2BEB8D717Q36843245-9E7C3C4E-DD64-4FE6-848E-2CE3934E6A02Q37353392-6F172399-BFF1-4EF9-9DCF-AD54F2CA5C07Q38533442-1A04C094-3D0F-40F2-B0CB-D4D16FF35C8CQ38936714-CF18BC48-B0A9-4DFF-9CA3-325C4619BBBDQ40560311-8E58C030-D89C-4C1E-9D66-C9C44DD9056EQ41207923-EB15DF09-6A22-4886-A782-010E309E17AEQ42714638-16FFBCED-5AA8-474B-91FE-76D6A2915499Q45963534-B70302AF-61CB-471B-9B9D-06F740C2ACF4Q46349157-803BFECD-22F7-49DC-AFD1-EE613485E773Q47109784-504C603A-9B40-4888-914E-7BF2E38B6ED4Q47159791-DD2F70D8-DF71-4AF9-8D45-C3D11ABF942AQ50118913-3F116D41-B8D1-4B54-9754-AAAC68428A0DQ50207951-46D48DBB-C0DA-4651-A679-6DEA4376C82CQ52867416-6FF18B6A-42FA-4566-8C9B-CD3D83DE6F16Q53608275-2D6F17F7-77D7-49BB-88D6-FC22BDC19F7E
P2860
Phase 1 study of the E-selectin inhibitor GMI 1070 in patients with sickle cell anemia
description
2014 nî lūn-bûn
@nan
2014 թուականին հրատարակուած գիտական յօդուած
@hyw
2014 թվականին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Phase 1 study of the E-selectin inhibitor GMI 1070 in patients with sickle cell anemia
@ast
Phase 1 study of the E-selectin inhibitor GMI 1070 in patients with sickle cell anemia
@en
Phase 1 study of the E-selectin inhibitor GMI 1070 in patients with sickle cell anemia
@nl
type
label
Phase 1 study of the E-selectin inhibitor GMI 1070 in patients with sickle cell anemia
@ast
Phase 1 study of the E-selectin inhibitor GMI 1070 in patients with sickle cell anemia
@en
Phase 1 study of the E-selectin inhibitor GMI 1070 in patients with sickle cell anemia
@nl
prefLabel
Phase 1 study of the E-selectin inhibitor GMI 1070 in patients with sickle cell anemia
@ast
Phase 1 study of the E-selectin inhibitor GMI 1070 in patients with sickle cell anemia
@en
Phase 1 study of the E-selectin inhibitor GMI 1070 in patients with sickle cell anemia
@nl
P2093
P2860
P3181
P1433
P1476
Phase 1 study of the E-selectin inhibitor GMI 1070 in patients with sickle cell anemia
@en
P2093
Anthony Cheung
Frans Kuypers
Helen Thackray
Henry Flanner
John L Magnani
Laura DeCastro
Lori Styles
Marilyn J Telen
Seungshin Rhee
P2860
P304
P3181
P356
10.1371/JOURNAL.PONE.0101301
P407
P577
2014-01-01T00:00:00Z